- Home
- YSG vs KLTOW Comparison
YSG vs KLTOW Comparison
Compare YSG & KLTOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YSG | KLTOW |
|---|---|---|
| Founded | 2016 | N/A |
| Country | China | United States |
| Employees | N/A | 3 |
| Industry | Package Goods/Cosmetics | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 889.0M | N/A |
| IPO Year | 2020 | 2022 |
Fundamental Metrics
Financial Performance| Metric | YSG | KLTOW |
|---|---|---|
| Price | $4.30 | $0.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 283.7K | N/A |
| Earning Date | 11-17-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $571,300,568.00 | N/A |
| Revenue This Year | $28.96 | N/A |
| Revenue Next Year | $16.57 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 22.59 | N/A |
| 52 Week Low | $3.01 | N/A |
| 52 Week High | $11.57 | N/A |
Technical Indicators
Market Signals| Indicator | YSG | KLTOW |
|---|---|---|
| Relative Strength Index (RSI) | 30.58 | 40.12 |
| Support Level | $4.15 | $0.13 |
| Resistance Level | $5.73 | $0.15 |
| Average True Range (ATR) | 0.40 | 0.02 |
| MACD | -0.09 | -0.00 |
| Stochastic Oscillator | 34.59 | 43.91 |
Price Performance
Historical ComparisonAbout YSG Yatsen Holding Limited
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.
About KLTOW Klotho Neurosciences Inc. Warrant
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.